Skip to main content
. 2013 Apr 29;6(1):220–226. doi: 10.3892/ol.2013.1323

Figure 3.

Figure 3.

(A) DFS and (B) OS curves for R-NSCLC patients who received adjuvant chemotherapy, according to class III β-tubulin expression. (A) DFS was inferior in the class III β-tubulin-low patients. DFS, disease-free survival; OS, overall survival; R-NSCLC, resected non-small cell lung cancer.